Canagliflozin
Brand names: Invokana
Part of: SGLT2 diabetes & heart drugs
At a glance
- Medicare prescriptions, 2024
- 114,951
- Medicare drug cost
- $97.4M
- Average cost per prescription
- $847
- Clinicians who prescribed it
- 6,249
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 32.3%
- Internal Medicine 25.5%
- Nurse Practitioners 14.2%
- Endocrinology & Diabetes 13.7%
- Physician Assistants 6.3%
- Nephrology (Kidney) 2.7%
- General Practice 1.5%
- Geriatric Medicine 1.2%
- Hospitalist 0.4%
- Cardiology 0.3%
- Adolescent Medicine 0.2%
- Psychiatric Nurse Practitioners 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 56% from 2019 to 2024.
Biggest change by state since 2019
- Minnesota −18%
- Michigan −20%
- Washington −30%
- Colorado −33%
- Oklahoma −35%
- Puerto Rico (smallest change) −76%
- Arkansas (smallest change) −75%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | white oval tablet, 17 mm | CFZ 300 |
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | yellow oval tablet, 11 mm | CFZ 100 |
| 300 mg | white oval tablet, 17 mm | CFZ 300 |
Janssen Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | yellow oval tablet, 11 mm | CFZ 100 |
| 300 mg | white oval tablet, 17 mm | CFZ 300 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $1,875 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Janssen Research & Development, LLC $1,875
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.